Tyra Biosciences, Inc.
TYRA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$20.42
KIRA · Stoqly’s AI analyst, in plain words
- Tyra Biosciences, Inc. lost $120M in fiscal 2025.
- Free cash flow was −$95.3M in fiscal 2025, — of revenue.
Market cap
$1.3B
P/E
—
Revenue
—
Net income
−$120M
Free cash flow
−$95.3M
Operating margin
—
Tyra Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$120M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tyra Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Tyra Biosciences, Inc.
- CIK
- 0001863127
Tyra Biosciences, Inc. · TYRA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$26.3M | −$55.3M | −$69.1M | −$86.5M | −$120M |
| Diluted EPS | −$1.91 | −$1.32 | −$1.62 | −$1.51 | −$2.01 |
| Cash | |||||
| Cash from operations | −$23.7M | −$50.3M | −$50.1M | −$69.8M | −$95.1M |
| Capital expenditure | $0.7M | $0.6M | $0.8M | $0.7M | $0.1M |
| Free cash flow | −$24.4M | −$50.8M | −$50.9M | −$70.4M | −$95.3M |
| Share count change | 793.6% | 203.9% | 2.0% | 34.0% | 4.2% |
| Debt and strength | |||||
| Cash and short-term investments | $302M | $251M | $58.0M | $92.0M | $77.4M |
| Shareholders' equity | $302M | $258M | $204M | $343M | $259M |
| Current ratio | 84.1x | 45.1x | 13.8x | 23.8x | 14.7x |
| Returns and quality | |||||
| Return on equity | −18.3% | −19.8% | −29.9% | −31.6% | −39.8% |
| Return on tangible equity | −8.7% | −21.5% | −33.8% | −25.2% | −46.3% |
| Altman Z'' | 69.2 | 36.0 | 10.9 | 19.5 | 9.9 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$10.6M
3 insiders
Of sales under plans
95%
$10.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tyra Biosciences, Inc. · TYRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $20.42 a share, the company is worth $1.3B.
Source: SEC EDGAR XBRL filings (CIK 0001863127). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.